X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2572) 2572
Publication (314) 314
Book Review (14) 14
Conference Proceeding (9) 9
Newsletter (4) 4
Dissertation (2) 2
Magazine Article (2) 2
Book Chapter (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2155) 2155
dacarbazine - analogs & derivatives (1676) 1676
dacarbazine - pharmacology (1362) 1362
index medicus (1331) 1331
oncology (1161) 1161
temozolomide (994) 994
cell line, tumor (897) 897
animals (860) 860
male (854) 854
female (848) 848
cancer (664) 664
antineoplastic agents, alkylating - pharmacology (647) 647
chemotherapy (646) 646
dacarbazine - administration & dosage (621) 621
mice (612) 612
adult (554) 554
middle aged (549) 549
dacarbazine - therapeutic use (530) 530
brain neoplasms - drug therapy (529) 529
glioblastoma (502) 502
glioblastoma - drug therapy (451) 451
aged (439) 439
pharmacology & pharmacy (439) 439
apoptosis (421) 421
antineoplastic combined chemotherapy protocols - therapeutic use (412) 412
dacarbazine (401) 401
antineoplastic agents - pharmacology (380) 380
brain neoplasms - pathology (375) 375
apoptosis - drug effects (359) 359
melanoma - drug therapy (336) 336
glioblastoma - pathology (333) 333
treatment outcome (312) 312
cell proliferation - drug effects (305) 305
melanoma (293) 293
glioma - drug therapy (284) 284
glioma (283) 283
antineoplastic agents, alkylating - therapeutic use (278) 278
tumors (258) 258
drug synergism (249) 249
expression (247) 247
cell survival - drug effects (245) 245
glioma - pathology (244) 244
drug resistance, neoplasm (237) 237
gliomas (236) 236
glioblastoma - metabolism (228) 228
glioblastoma multiforme (224) 224
xenograft model antitumor assays (223) 223
melanoma - pathology (215) 215
dacarbazine - adverse effects (214) 214
brain neoplasms - metabolism (213) 213
dose-response relationship, drug (212) 212
therapy (200) 200
analysis (198) 198
glioblastoma - genetics (198) 198
mice, nude (197) 197
malignant glioma (196) 196
brain neoplasms - genetics (195) 195
cell biology (195) 195
combined modality therapy (192) 192
survival (192) 192
antineoplastic agents - therapeutic use (191) 191
tumor cells, cultured (188) 188
radiotherapy (180) 180
antineoplastic agents (176) 176
antineoplastic agents, alkylating - administration & dosage (167) 167
article (164) 164
metastatic melanoma (164) 164
adolescent (163) 163
antineoplastic combined chemotherapy protocols - adverse effects (157) 157
cells (155) 155
research (155) 155
antimitotic agents (154) 154
antineoplastic combined chemotherapy protocols - pharmacology (153) 153
care and treatment (153) 153
in-vitro (152) 152
prognosis (150) 150
dna repair (148) 148
medicine & public health (147) 147
disease-free survival (146) 146
cancer therapies (144) 144
cytotoxicity (144) 144
brain tumors (143) 143
glioma - metabolism (143) 143
resistance (141) 141
dna damage (139) 139
survival analysis (139) 139
doxorubicin - administration & dosage (138) 138
medicine, research & experimental (138) 138
skin neoplasms - drug therapy (138) 138
brain cancer (135) 135
gene expression regulation, neoplastic - drug effects (135) 135
malignant-melanoma (135) 135
drug resistance, neoplasm - drug effects (131) 131
rats (131) 131
time factors (131) 131
trial (128) 128
adjuvant temozolomide (125) 125
biochemistry & molecular biology (125) 125
health aspects (125) 125
gene expression (123) 123
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2535) 2535
Japanese (11) 11
Chinese (8) 8
Italian (6) 6
French (5) 5
German (3) 3
Russian (3) 3
Spanish (3) 3
Hungarian (2) 2
Polish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cell Stem Cell, ISSN 1934-5909, 03/2009, Volume 4, Issue 3, pp. 226 - 235
In normal brain, the side population (SP) phenotype is generated by ABC transporter activity and identifies stem cell and endothelial cell subpopulations by... 
STEMCELL | CANCER-CELLS | SURVIVAL | GLIOBLASTOMA | TRANSPORTER | IN-VIVO | DISTINCT | DRUG-RESISTANCE | MULTIDRUG-RESISTANCE | EXPRESSION | TEMOZOLOMIDE | CELL & TISSUE ENGINEERING | CELL BIOLOGY | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Neoplastic Stem Cells - drug effects | Humans | Antineoplastic Agents, Alkylating - pharmacology | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Neoplasm Proteins - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Glioma - metabolism | Brain - metabolism | Neoplastic Stem Cells - metabolism | Dacarbazine - pharmacology | Glioma - pathology | Dacarbazine - analogs & derivatives | ATP-Binding Cassette Transporters - metabolism | Neoplastic Stem Cells - pathology | Antineoplastic Agents - pharmacology | Chromones - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | PTEN Phosphohydrolase - genetics | Cells, Cultured | Dacarbazine - metabolism | Enzyme Inhibitors - pharmacology | Glioma - chemically induced | Morpholines - pharmacology | PTEN Phosphohydrolase - metabolism | Platelet-Derived Growth Factor - pharmacology | Blood-Brain Barrier - metabolism | Animals | Mice, Nude | Brain - pathology | Mice | Mitoxantrone - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Antineoplastic Agents, Alkylating - metabolism | Index Medicus | PTEN | Akt | Glioma | Side Population | ABCG2
Journal Article
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 403, pp. 98 - 107
Abstract Organometallic complexes offer the prospect of targeting multiple pathways that are important in cancer biology. Here, the preclinical activity and... 
Hematology, Oncology and Palliative Medicine | Thioredoxin reductase inhibitor | Silver-N-heterocyclic carbene | PARP1 inhibitor | Topoisomerase inhibitor | Glycolytic inhibitor | TARGET | APOPTOSIS | DNA-BINDING | MAMMALIAN THIOREDOXIN | CANCER | ONCOLOGY | THIOREDOXIN REDUCTASE | AGENTS | INHIBITORS | TUMOR-GROWTH | CYTOTOXICITY | Neoplasms - metabolism | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Imidazoles - chemistry | Drug Resistance, Neoplasm | Glycolysis - drug effects | Antineoplastic Agents - toxicity | Antineoplastic Combined Chemotherapy Protocols - pharmacology | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Topoisomerase I Inhibitors - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antigens, Neoplasm - metabolism | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Imidazoles - toxicity | Cell Survival - drug effects | DNA Topoisomerases, Type II - metabolism | Organometallic Compounds - toxicity | DNA Topoisomerases, Type I - metabolism | Poly (ADP-Ribose) Polymerase-1 - metabolism | Imidazoles - pharmacology | Topoisomerase II Inhibitors - pharmacology | Cisplatin - pharmacology | Antineoplastic Agents - chemistry | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Neoplasms - drug therapy | Drug Synergism | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Signal Transduction - drug effects | Cell Line, Tumor | Thioredoxin Reductase 1 - antagonists & inhibitors | Organometallic Compounds - chemistry | DNA Damage | Oxidative Stress - drug effects | Neoplasms - pathology | Organometallic Compounds - pharmacology | Thioredoxin Reductase 1 - metabolism | Glucose metabolism | Enzymes | Care and treatment | Cell death | Heterocyclic compounds | DNA damage | Cancer | Flow cytometry | Reactive oxygen species | Toxicity | Cytotoxicity | Biology | Thioredoxin | Kinases | Cancer therapies | DNA repair | Anticancer properties | Fibers | Pathways | Inhibition | Coordination compounds | Deoxyribonucleic acid--DNA | Gold | Damage assessment | DNA topoisomerase | Organometallic complexes | Cisplatin | Silver | Poly(ADP-ribose) Polymerase 1 | Glycolysis | Ligands | Temozolomide | Tumors | Apoptosis | Reductase
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2016, Volume 139, Issue 9, pp. 2047 - 2055
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on chromatin, acting as... 
blood brain barrier | glioblastoma | BET inhibitor | OTX015 (MK‐8628) | combination studies | Combination studies | Blood brain barrier | Glioblastoma | OTX015 (MK-8628) | SELECTIVE-INHIBITION | C-MYC | ACUTE MYELOID-LEUKEMIA | MALIGNANT GLIOMA | ONCOLOGY | RECURRENT | BROMODOMAIN INHIBITION | TARGETS | PROTEINS | SMALL-MOLECULE INHIBITION | BRD4 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Acetanilides - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Everolimus - administration & dosage | Antineoplastic Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Camptothecin - analogs & derivatives | Cell Survival - drug effects | Acetanilides - pharmacology | Dacarbazine - administration & dosage | Everolimus - pharmacology | Brain Neoplasms - drug therapy | Blood-Brain Barrier - drug effects | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 3-Ring - administration & dosage | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Glioblastoma - drug therapy | Camptothecin - pharmacology | Epigenetic inheritance | Chemotherapy | Chromatin | RNA | Lysine | Analysis | Brain tumors | Gene expression | Glioblastoma multiforme | Protein binding | Cancer | Epigenetics | Cancer therapies | Brain cancer | Tumors
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 09/2015, Volume 43, Issue 9, pp. 1360 - 1371
Effective treatments for primary brain tumors and brain metastases represent a major unmet medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway... 
BREAST-CANCER | MALIGNANT GLIOMA | DRUG DISCOVERY | BARRIER | METASTASES | PHASE-II | PHARMACOLOGY & PHARMACY | BLOOD-BRAIN | DEPENDENT KINASES | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Brain Neoplasms - pathology | Male | Aminopyridines - therapeutic use | Benzimidazoles - administration & dosage | Dacarbazine - analogs & derivatives | Madin Darby Canine Kidney Cells | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Aminopyridines - administration & dosage | Dacarbazine - administration & dosage | Pyridines - administration & dosage | Rats | Piperazines - therapeutic use | Brain Neoplasms - drug therapy | Piperazines - pharmacology | Brain - drug effects | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Glioblastoma - pathology | Dogs | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Glioblastoma - drug therapy
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2012, Volume 106, Issue 5, pp. 858 - 866
BACKGROUND: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical... 
temozolomide | scheduling | apoptosis | Selumetinib | barasertib | docetaxel | PROTEIN | PHOSPHORYLATION | MAP KINASE | G/M TRANSITION | MULTIPLE-MYELOMA CELLS | SPINDLE-CHECKPOINT | IN-VITRO | ONCOLOGY | MELANOMA-CELLS | KINASE KINASE INHIBITION | PHASE-I | Taxoids - pharmacology | Apoptosis - drug effects | Dacarbazine - therapeutic use | Humans | Organophosphates - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasms, Experimental - pathology | Taxoids - therapeutic use | Benzimidazoles - administration & dosage | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Benzimidazoles - therapeutic use | Organophosphates - administration & dosage | MAP Kinase Kinase 1 - antagonists & inhibitors | Dacarbazine - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Organophosphates - pharmacology | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Mice, Nude | Quinazolines - therapeutic use | Cell Line, Tumor | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Neoplasms, Experimental - drug therapy | Translational Therapeutics
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2018, Volume 81, Issue 3, pp. 455 - 460
The purpose of this report is to describe, for the first time, the pharmacokinetics of dacarbazine (DTIC) and its metabolites... 
Pregnancy | Dacarbazine | Medicine & Public Health | Metabolites | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | TRIMESTER | CANCER | METABOLITE 5-AMINOIMIDAZOLE-4-CARBOXAMIDE | WOMEN | PLASMA | 24-HOUR CREATININE CLEARANCE | ONCOLOGY | POSTPARTUM | CYP1A2 | NON-HODGKINS-LYMPHOMA | PHARMACOLOGY & PHARMACY | Dacarbazine - adverse effects | Area Under Curve | Hodgkin Disease - pathology | Humans | Antineoplastic Agents, Alkylating - administration & dosage | Drug Monitoring - methods | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antineoplastic Agents, Alkylating - blood | Hodgkin Disease - drug therapy | Pregnancy Complications, Neoplastic - drug therapy | Adult | Dacarbazine - pharmacokinetics | Female | Infant, Newborn | Dacarbazine - administration & dosage | Treatment Outcome | Antineoplastic Agents, Alkylating - pharmacokinetics | Pregnancy Complications, Neoplastic - pathology | Administration, Intravenous | Dacarbazine - blood | Bleomycin - pharmacology | Vinblastine - pharmacology | Antineoplastic Agents, Alkylating - adverse effects | Neoplasm Staging | Doxorubicin - pharmacology | Pregnancy Outcome | Anthracyclines | Lymphomas | Pregnant women | Vinblastine | Cytochrome P450 | Case reports | Pharmacology | Liquid chromatography | Gestation | CYP1A2 protein | Metabolism | High-performance liquid chromatography | Doxorubicin | Lymphoma | Postpartum | Bleomycin | Imidazole | Drug metabolism | Remission
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2015, Volume 76, Issue 5, pp. 977 - 987
Children with high-risk neuroblastoma have poor survival rates, and novel therapies are needed. We hypothesized that cabozantinib would be effective against... 
RET | Cabozantinib | XL184 | Medicine & Public Health | Oncology | Cancer Research | Neuroblastoma | Pharmacology/Toxicology | Retinoic acid | ERK | REFRACTORY NEUROBLASTOMA | MEDULLARY-THYROID CANCER | GROWTH-FACTOR RECEPTORS | 13-CIS-RETINOIC ACID | PHASE-II | CHILDRENS ONCOLOGY GROUP | PRECLINICAL TESTING PROGRAM | ONCOLOGY | PHARMACOLOGY & PHARMACY | HIGH-RISK NEUROBLASTOMA | NEURO-BLASTOMA CELLS | Adrenal Gland Neoplasms - drug therapy | Anilides - therapeutic use | Humans | Neuroblastoma - enzymology | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Inhibitory Concentration 50 | Neuroblastoma - pathology | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Pyridines - therapeutic use | Cell Survival - drug effects | Topotecan - pharmacology | Administration, Oral | Isotretinoin - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Anilides - pharmacology | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Immunocompromised Host | Medical colleges | Chemotherapy | Analysis | Tretinoin | Cancer
Journal Article